Develops in vitro diagnostic solutions for infectious diseases. Produces diagnostic systems for cardiovascular pathologies. Now — the numbers.
This is an established company with proven profits.
No real growth (5% a year).
The market pays 22× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 43% below its peak. The market has trimmed its expectations for the company.
There is $660.9M in the vault; even if every debt were paid off, $125.7M would remain.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.